Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines

References

• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–762.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259–263.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059–1065.
   PubMed Web of Science ®Google Scholar
• Hatakeyama M, Brill JA, Fink GR, et al. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 1994;8:1759–1771.
   PubMed Web of Science ®Google Scholar
• Calbo J, Parreno M, Sotillo E, et al. G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem. 2002;277:50263–50274.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111:5683–5690.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121:1394–1402.
   PubMed Web of Science ®Google Scholar
• Sonoki T, Harder L, Horsman DE, et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 2001;98:2837–2844.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:1740–1745.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119:4597–4607.
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744–1750.
   PubMed Web of Science ®Google Scholar
• Kornmann M, Danenberg KD, Arber N, et al. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 1999;59:3505–3511.
   PubMed Web of Science ®Google Scholar
• Biliran H, Jr.,Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11:6075–6086.
   PubMed Web of Science ®Google Scholar
• Noel EE, Yeste-Velasco M, Mao X, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176:2607–2615.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Yanaihara N, Okamoto A, et al. Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med. 2011;2:213–219.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Tiemann K, Alluin JV, Honegger A, et al. Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines. Leuk Lymphoma. 2011;52:2148–2154.
   PubMed Web of Science ®Google Scholar
• M’Kacher R, Farace F, Bennaceur-Griscelli A, et al. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet. 2003;143:32–38.
   PubMed Web of Science ®Google Scholar
• Amin HM, McDonnell TJ, Medeiros LJ, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003;127:424–431.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441:106–110.
   PubMed Web of Science ®Google Scholar
• Frum RA, Deb S, Deb SP. Use of the DNA fiber spreading technique to detect the effects of mutant p53 on DNA replication. Methods Mol Biol. 2013;962:147–155.
   PubMedGoogle Scholar
• Pinyol M, Bea S, Pla L, et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood. 2007;109:5422–5429.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–5868.
   PubMed Web of Science ®Google Scholar
• Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2007;2:1084–1104.
   PubMed Web of Science ®Google Scholar
• Osborn AJ, Elledge SJ, Zou L. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol. 2002;12:509–516.
   PubMed Web of Science ®Google Scholar
• Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia. 2008;22:2097–2105.
   PubMed Web of Science ®Google Scholar
• Weinstein S, Emmanuel R, Jacobi AM, et al. RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PLoS One. 2012;7:e43343
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474:230–234.
   PubMed Web of Science ®Google Scholar
• Petermann E, Orta ML, Issaeva N, et al. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell. 2010;37:492–502.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Ray Chaudhuri A, Lopes M, et al. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat Struct Mol Biol. 2010;17:1305–1311.
   PubMed Web of Science ®Google Scholar
• Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Ma J, Lu P, Guo A, et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol. 2014;166:849–861.
   PubMed Web of Science ®Google Scholar